Visual trajectory | Visual trajectory | ||||||
---|---|---|---|---|---|---|---|
Episodic SMS-based pattern | Persistent fluctuating SMS-based pattern | ||||||
Single episode | Episodic | Mild ongoing | Fluctuating | Episodic | Mild ongoing | Fluctuating | |
Number, n | 91 | 225 | 35 | 65 | 104 | 47 | 253 |
Weekly SMS-based details | |||||||
Total number of days with pain, median (IQR) | 100 (81–118) | 122 (103–146) | 134 (112–172) | 154 (130–208) | 183 (154–210) | 211 (176–268) | 273 (221–352) |
Proportion (%) of weeks, median (IQR) | |||||||
Minor pain (< 2) | 80 (67–90) | 61 (46–78) | 60 (43–76) | 44 (33–56) | 17 (8–29) | 10 (0–24) | 2 (0–8) |
Mild pain (≥ 2 < 4) | 13 (6–24) | 21 (13–31) | 21 (13–39) | 22 (14–33) | 41 (28–55) | 52 (33–71) | 29 (12–44) |
Moderate pain (≥ 4 < 6) | 4 (2–8) | 8 (4–20) | 8 (2–16) | 17 (12–25) | 25 (14–37) | 25 (13–37) | 35 (23–47) |
Severe pain intensity (≥ 6) | 0 (0–2) | 2 (0–6) | 2 (0–4) | 6 (4–19) | 8 (2–16) | 2 (0–8) | 19 (6–41) |
Mean pain intensity, median (IQR)a | 0.6 (0.3–1.1) | 1.4 (0.9–2.0) | 1.4 (0.9–1.9) | 2.1 (1.6–3.0) | 2.7 (2.3–3.4) | 3.0 (2.4–3.5) | 4.3 (3.4–5.1) |
Longest pain-free period (weeks), median (IQR) | 19 (10–28) | 8 (5–14) | 7 (5–13) | 7 (5–9) | 2 (1–2) | 1 (0–2) | 0 (0–1) |
No pain last four weeks, % | 67 | 33 | 20 | 15 | 0 | 0 | 0 |
Number of pain-free periods, median (IQR) | 1 (0–2) | 2 (1–3) | 1 (1–2) | 2 (1–3) | 1 (0–2) | 0 (0–1) | 0 (0–0) |
Longest painful period (weeks), median (IQR) | 4 (3–9) | 7 (4–11) | 9 (4–12) | 9 (6–14) | 16 (10–28) | 16 (10–39) | 26 (13–50) |
Stable SMS-based pattern, yes % | 25 | 44 | 46 | 58 | 99 | 100 | 100 |
1-year patient characteristics | |||||||
Pain intensity, median (IQR) | 0 (0–0) | 0 (0–2) | 1 (0–3) | 3 (0–5) | 3 (2–5) | 3 (2–4) | 4 (3–6) |
Recovery expectations, median (IQR) | 1 (0–2) | 4 (2–7) | 5 (2–8) | 8 (5–10) | 7 (4.5–9) | 7 (5–10) | 9 (7–10) |
Örebro screening questionnaire, median (IQR) | 17 (11–25) | 27 (19–34) | 27 (21–39) | 37 (30–49) | 35 (28–44) | 34 (26–40) | 47 (40–55) |
HSCL-10, median (IQR) | 1.1 (1.0–1.5) | 1.3 (1.1–1.6) | 1.3 (1.1–1.5) | 1.4 (1.2–1.8) | 1.5 (1.2–1.7) | 1.5 (1.2–1.9) | 1.6 (1.3–2.0) |
NDI, median (IQR) | 2 (1–4) | 6 (3–9) | 6 (4–9) | 12 (8–15) | 9 (6–12) | 8 (5–13) | 15 (11–19) |
Baseline patient characteristics | |||||||
Pain intensity, median (IQR) | 3 (1–4) | 3 (2–5) | 2 (1–4) | 4 (3–6) | 4 (3–6) | 4 (3–5) | 5 (4–6) |
Proportion of patients with positive change scoreb, % | |||||||
NDI | 43 | 30 | 23 | 31 | 22 | 21 | 13 |
Örebro screening questionnaire | 40 | 27 | 29 | 23 | 19 | 13 | 29 |
HSCL-10 | 25 | 20 | 31 | 29 | 20 | 13 | 18 |
Recovery expectation | 63 | 52 | 31 | 26 | 38 | 30 | 26 |